Evidence map›Paper›PMID 40469084›Full record

ArticleBone reports2025

Diagnosis of skeletal fragility due to Loeys-Dietz syndrome and treatment with romosozumab followed by denosumab.

Yasutaka Tsujimoto, Naoki Yamamoto, Hayato Fukumitsu, Hironori Bando, Masaaki Yamamoto, Keiko Tanaka, Naoya Morisada, Miwako Nagasaka, Keisuke Oe, Takahiro Niikura and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yasutaka TsujimotoDivision of Diabetes and Endocrinology, Department of Internal Medicine, Graduate School of Medicine, Kobe University, Kobe, Japan.
Naoki YamamotoDivision of Diabetes and Endocrinology, Department of Internal Medicine, Graduate School of Medicine, Kobe University, Kobe, Japan.
Hayato FukumitsuDivision of Diabetes and Endocrinology, Department of Internal Medicine, Graduate School of Medicine, Kobe University, Kobe, Japan.
Hironori BandoDivision of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Hospital, Kobe, Japan.
Masaaki YamamotoDivision of Diabetes and Endocrinology, Department of Internal Medicine, Graduate School of Medicine, Kobe University, Kobe, Japan.
Keiko TanakaDepartment of Medical Genetics, Kobe University Hospital, Kobe, Japan.
Naoya MorisadaDepartment of Pediatrics, Graduate School of Medicine, Kobe University, Kobe, Japan.
Miwako NagasakaDepartment of Clinical and Molecular Genetics, Takatsuki General Hospital, Takatsuki, Japan.
Keisuke OeDepartment of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Takahiro NiikuraDepartment of Orthopaedic Surgery and Division of Rehabilitation, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan.
Mika YamauchiResearch Institute for Metabolic Bone Diseases, Eikokai Ono Hospital, Ono, Japan.
Wataru OgawaDivision of Diabetes and Endocrinology, Department of Internal Medicine, Graduate School of Medicine, Kobe University, Kobe, Japan.
Hidenori FukuokaDivision of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Hospital, Kobe, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Loeys-Dietz syndrome (LDS) is an autosomal dominant, inherited connective tissue disorder caused by a pathogenic variant in TGF-β signaling-related genes. LDS is associated with a high risk of low bone mineral density (BMD) and fractures. We present a case report of a 43-year-old premenopausal woman with skeletal fragility who was diagnosed with LDS type 4 due to a large heterozygous deletion in the

Indexed as

DenosumabLoeys–Dietz syndromeMarfan syndromeOsteoporosisRomosozumabSequential therapySkeletal fragility

Identifiers

PMID40469084
PMCPMC12135386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.